Evidence map›Paper›PMID 29805718›Full record

ArticleEuropean scientific journal2017

Potential Alzheimer's Disease Therapeutics Among Weak Cysteine Protease Inhibitors Exhibit Mechanistic Differences Regarding Extent of Cathepsin B Up-Regulation and Ability to Block Calpain.

Heather Romine, Katherine M Rentschler, Kaitlan Smith, Ayanna Edwards, Camille Colvin, Karen Farizatto, Morgan C Pait, David Butler, Ben A Bahr

Open access · diamondAbstract read
In one paragraph

Article in European scientific journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. In vitro antitumor effects and apoptosis-related mechanisms of lidocaine in renal cell carcinoma A498 cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Effect ofInternational journal of ophthalmology · 2021
    Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Heather RomineUniversity of North Carolina - Pembroke, Pembroke, North Carolina, USA.
Katherine M RentschlerUniversity of North Carolina - Pembroke, Pembroke, North Carolina, USA.
Kaitlan SmithUniversity of North Carolina - Pembroke, Pembroke, North Carolina, USA.
Ayanna EdwardsUniversity of North Carolina - Pembroke, Pembroke, North Carolina, USA.
Camille ColvinUniversity of North Carolina - Pembroke, Pembroke, North Carolina, USA.
Karen FarizattoUniversity of North Carolina - Pembroke, Pembroke, North Carolina, USA.
Morgan C PaitUniversity of North Carolina - Pembroke, Pembroke, North Carolina, USA.
David ButlerCenter for Drug Discovery, Northeastern University, Boston, Massachusetts, USA.
Ben A BahrWilliam C. Friday Laboratory, University of North Carolina - Pembroke, North Carolina, USA.
University of North Carolina at Pembroke · USNortheastern University · US

Funding

UNCP RISE Option 2R25GM077634 · NIGMS · UNIVERSITY OF NORTH CAROLINA AT PEMBROKE · PI SMITH, RACHEL B. · 2006 to 2021
$4.3M
NIGMS NIH HHS R25 GM077634
6 · The paper itself

Abstract

Cysteine protease inhibitors have long been part of drug discovery programs for Alzheimer's disease (AD), traumatic brain injury (TBI), and other disorders. Select inhibitors reduce accumulating proteins and AD pathology in mouse models. One such compound, Z-Phe-Aladiazomethylketone (PADK), exhibits a very weak IC

Indexed as

Alzheimer’s diseasecalpainE64dlysosomePADK

Identifiers

PMID29805718
PMCPMC5967645
OpenAlexW2767266822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.